Core Clinical Trials Backing Vascepa
Vascepa (icosapent ethyl) relies on two pivotal trials for its FDA approvals and patient support materials. The REDUCE-IT trial showed a 25% relative risk reduction in major cardiovascular events (MVO—heart attacks, strokes, CV death, revascularization) versus placebo in high-risk statin patients, with absolute risk reduction of 4.8% over 4.9 years.[1] The MARINE and ANCHOR trials established efficacy for severe hypertriglyceridemia, reducing triglycerides by 33-45% without increasing LDL-C.[2]
How These Papers Support Patient Aid Programs
Patient assistance for Vascepa, like the VASCEPA Savings Card or Patient Assistance Program via Amarin or Cosyntus, often references these trials to justify eligibility (e.g., CV risk or TG ≥500 mg/dL). Programs cover copays up to $13,000/year for eligible commercially insured patients, citing trial data on outcomes to guide HCP prescriptions and patient education handouts.[3]
Key Publications and Access
- REDUCE-IT (NEJM 2019): Bhatt DL et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." Primary endpoint: composite MVE HR 0.75 (p<0.001).[1] Link
- MARINE/ANCHOR (NEJM 2012/2014): Jacobson TA et al. TG reductions in TG 500-2000 mg/dL (MARINE) and 200-500 mg/dL (ANCHOR) on fibrates/statins.[2] MARINE Link | ANCHOR Link
- Labeling Summary (FDA/EVENITY): Integrates trial data for patient info; essential for aid verification.[4] FDA Label
Regulatory and Patent Ties for Aid Access
FDA approvals (2012 for TG, 2020 CV) stem from these papers, influencing aid availability until patents expire (e.g., method-of-use '057 patent challenged, potential 2039 expiry).[5] No generics yet, so aid programs remain active for branded Vascepa.
Patient Resources Referencing Papers
Aid kits from AmarinCorp.com include trial summaries for adherence counseling; EVRYSD Patient Services uses REDUCE-IT data for CV risk screening.[3][6]
Sources
[1] NEJM REDUCE-IT
[2] NEJM/JAMA MARINE-ANCHOR
[3] Amarin VASCEPA Support
[4] FDA Vascepa Label
[5] DrugPatentWatch Vascepa
[6] EVRYS Patient Services